GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

This study is testing two different drug combinations for people with advanced stomach or gastroesophageal junction cancer whose disease has continued to grow despite receiving first-line immunotherapy. Researchers want to see if adding a third drug to a two-drug combination is m…

This is the first study in people for a new drug called KK2269. It aims to find a safe dose and see how well the body tolerates it. The study will test KK2269 alone in people with various advanced solid tumors, and also test it combined with a standard chemotherapy drug (docetaxe…

This early-stage study is testing a new nanoparticle treatment called NBTXR3 for people with esophageal cancer. The nanoparticles are injected directly into the tumor and are designed to make radiation therapy more effective at killing cancer cells when combined with standard che…

This study is observing how well a new targeted drug called zolbetuximab works when combined with standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has spread. It aims to confirm the drug's effectiveness and safety in real-world patie…

This study is testing if a stomach cancer drug called tislelizumab works just as well when given as a simple injection under the skin, compared to the standard method of a slow infusion into a vein. It will involve about 351 adults with advanced stomach cancer who have not yet re…

This early-stage study is testing the safety and effects of an experimental cancer drug called PF-08046876 in adults with advanced solid tumors. The drug is an antibody drug conjugate designed to target and kill cancer cells. Researchers will give the drug through an IV to about …

This study is testing whether a new drug called BL-M07D1 works better than standard chemotherapy for people with advanced HER2-positive stomach or gastroesophageal cancer. It's for patients whose cancer has continued to grow despite their first round of treatment. The main goals …

This study is testing a new combination of two cancer drugs, disitamab vedotin and tucatinib, for people with advanced or spreading breast or stomach cancer. The main goals are to find a safe and effective dose and to see if the combination can shrink tumors. It is for people who…

This study is testing whether adding a new oral drug called SHR2554 to other cancer treatments is safe and effective for people with advanced stomach cancer that has spread or cannot be removed by surgery. It will involve about 351 adults with this condition. The main goals are t…

This trial is testing a personalized cell therapy called CT041 for people with advanced stomach or gastroesophageal junction cancer. After completing standard first-line treatment, participants will have their own immune cells collected, genetically modified to target their cance…

This study is testing a two-part treatment for stomach cancer that has spread to the abdominal lining. Doctors use a robotic system to perform minimally invasive surgery to remove visible tumors, then bathe the area with heated chemotherapy. The goal is to see if this combined ap…

This early-stage study aims to find the safest dose of a powerful combination of five chemotherapy drugs for people with advanced cancers of the stomach, pancreas, and related areas. It uses a patient's genetic test results to personalize the dose of one key drug, hoping to reduc…

This study is testing a new oral medication called NEO212 for adults with specific aggressive brain tumors (like glioblastoma) or brain metastases from other cancers. The main goals are to find a safe and effective dose, see how the body processes the drug, and check if it can he…

This large Phase 3 study is testing whether adding new targeted drugs to standard chemotherapy works better for people with advanced stomach, esophageal, or gastroesophageal junction cancers. The trial is specifically for patients whose cancers test positive for a protein called …

This study is testing a new combination treatment for people with a type of stomach cancer that is advanced but hasn't spread to distant organs. The goal is to see if adding a shorter, more intense course of radiation to standard immunotherapy and chemotherapy can shrink tumors e…

This large Phase 3 trial is testing whether a new combination of cancer drugs works better than current standard treatment for advanced HER2-positive stomach cancer. The study will enroll 840 patients with previously untreated, advanced stomach or gastroesophageal junction cancer…

This study is testing a new oral drug called zongertinib for adults with advanced HER2-positive cancers that have spread and stopped responding to prior treatments. The main goals are to find the safest and most effective dose of zongertinib when given alone or combined with othe…

This study is testing a new combination of drugs for adults with advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be removed by surgery. Researchers want to find the safest and most effective dose of an experimental drug (telisotuzumab adizutecan) whe…

This early-stage trial is testing the safety and dosing of an experimental drug called PF-08046050 in adults with advanced solid tumors that have returned or stopped responding to standard treatments. The drug is designed to attach to cancer cells and deliver a toxic payload dire…

This study is testing if adding a chemotherapy drug (paclitaxel) directly into the abdominal cavity, along with standard IV chemotherapy, works better than standard IV chemotherapy alone for people with advanced stomach cancer that has spread to the lining of the abdomen. Partici…

This early-stage study is testing whether adding an immune-boosting drug directly into the abdomen, along with standard immunotherapy and chemotherapy, can better treat stomach cancer that has spread to the abdominal lining. The goal is to see if this combination can reduce the a…

This study is testing if adding the drug tadalafil (Cialis) to standard chemotherapy before stomach cancer surgery is safe and helpful. Researchers want to see if this combination changes the environment around the tumor to make treatment more effective. About 10 patients with op…

This study is testing if adding a newer drug (liposomal irinotecan) to a standard, strong pre-surgery treatment plan works better for people with advanced cancer where the stomach meets the esophagus. The goal is to shrink the tumor as much as possible before surgery, aiming for …

This study is testing whether adding a shorter, more intense course of radiation to immunotherapy and chemotherapy before surgery is safe and more effective for people with a type of cancer where the stomach meets the esophagus. The goal is to see if this combination can complete…

This early-stage trial is testing an experimental drug called sigvotatug vedotin for people with advanced solid tumors that have spread or cannot be removed by surgery. The study will first determine safe doses, then test the drug alone and in combination with other cancer medica…

This study is testing whether giving a cancer immunotherapy treatment called nivolumab as an injection at home is a safe and practical alternative to receiving it at a clinic. It aims to see if home treatment reduces the burden of travel and improves quality of life for patients …

This study aims to collect blood and tissue samples to help develop a single blood test that can detect many different cancers early. Researchers will enroll 2,000 people, including those with cancer and those without, to create a reference set for testing. The goal is to validat…

This study is a national registry that aims to collect information on how patients with advanced stomach or esophageal cancer are actually treated in everyday practice in Germany. It will follow about 1,900 patients for up to two years to understand common treatment sequences and…